Replimune gives an update on RP1 Clinical Development Program in CSCC
Category: #health  By Mateen Dalal  Date: 2019-10-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Replimune gives an update on RP1 Clinical Development Program in CSCC

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer caused because of the uncontrolled growth of abnormal squamous cells. Currently, Libtayo is the only approved treatment in the Brazil and United States, and conditionally approved treatment in the Canada and European Union, for the treatment of locally advanced or metastatic CSCC.

Replimune Group Inc., a biotechnology company pioneering a new generation of oncolytic immuno-gene therapies, however, has reportedly announced that it has enrolled the first patient for its randomized, registration-directed, controlled Phase 2 clinical study of RP1.

The clinical study is being conducted in combination with Regeneron and Sanofi’s Libtayo® compared to Libtayo alone in patients who are suffering from CSCC.

Sources cite that initial data garnered from this clinical trial firmly supports the utility of RP1 in CSCC. Replimune has also announced its plan to begin another clinical trial of RP1 as monotherapy in organ transplant receiver with CSCC in early 2020.

According to Robert Coffin, Ph.D., CEO and President of Replimune, the company is delighted to announce the initiation of its first registration-directed clinical trial and data garnered for RP1 is strongly supportive.

Reportedly, the Phase 2 clinical study of RP1 is randomized, multi-center, and controlled clinical trial and is anticipated to register approximately 240 patients. Its main goal is to assess the response rate of RP1 with Libtayo against the response rate with Libtayo alone. This clinical study is conducted with Replimune’s collaboration agreement with Regeneron.

Reliable sources further claim that the full Phase 1 clinical efficacy, safety and biomarker data from this clinical trial, which Replimune expects will further support the overall clinical advancement strategy for RP1, is scheduled to be demonstrated at SITC (The Society For Immunotherapy of Cancer) Annual Meeting in National Harbor, Maryland on November 8, 2019.

Source Credit - https://www.biospace.com/article/releases/replimune-provides-update-on-rp1-clinical-development-program-in-cutaneous-squamous-cell-carcinoma/

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...